E
ORIC icon

Ergoteles’s Oric Pharmaceuticals ORIC Stock Holding History

Ergoteles’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-42,523
Closed -$250K – 1629
2022
Q4 		$250K Sell
42,523
-41,312
-49% -$139K 0.01% 982
2022
Q3 		$268K Sell
83,835
-69,265
-45% -$277K 0.01% 1034
2022
Q2 		$686K Buy
+153,100
New +$611K 0.02% 702

Other funds holding ORIC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Ergoteles's ORIC Position: Q1 2023 in Review

Ergoteles sold out of Oric Pharmaceuticals (ORIC) in Q1 2023, closing a stake of 42,523 shares — an estimated $250K sold.

Ergoteles first reported a position in ORIC in Q2 2022 and held it in 3 quarters. The position peaked at $686K in Q2 2022. 70 funds tracked by Wall St. Rank hold ORIC as of Q1 2023.

  • Ergoteles reported no remaining Oric Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 42,523 Oric Pharmaceuticals shares in Q1 2023, an estimated $250K.
  • Ergoteles first reported a position in Oric Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • Ergoteles's Oric Pharmaceuticals position peaked at $686K in Q2 2022.
  • 70 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.